Tracer library / [131I]KN046

[131I]KN046

Also written as [I-131]KN046

Radionuclide: I-131 t½ 11549 min
Modality: Therapy
Production route: —
Stage: Reported once
Syntheses indexed: 1

Melanoma Immune cell and immunotherapy imaging

What it is

Compound class: Bispecific single-domain antibody-Fc fusion protein (anti-PD-L1/CTLA-4)
Target / mechanism: PD-L1 and CTLA-4 dual targeting PMID 36242616
Clinical application: Radioimmunotherapy for malignant melanoma, enhancing antitumor immune response PMID 36242616
Theranostic pair: —

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis	—	none	99.99%	—	KN046	36242616 2023 Eur J Nucl Med Mol Imaging KN046 was labeled with [131I] using the catalyst iodogen. - The initial labeling yield of [131I]-KN046 was 99.99%

Need this precursor?We can point you to suppliers for [131I]KN046, or handle the enquiry for you.

Get in touch

Notes

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 36242616. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty.